dna-g3fb1563d6_1920.jpg

Endocrine Disruption

The evaluation of substances for Endocrine Disruption (ED) potential is a growing concern from a regulatory perspective. This evaluation has been mandatory since 2018 under the Plant Protection Products and Biocide Products regulations. The year 2022 is expected to be a key turning point with the update of the regulation on Cosmetic Products and the addition of classification criteria for endocrine disruptors in the CLP regulation. Moreover, in the same year, REACH will be updated with new requirements to identify endocrine disruptors.

The evaluation of the ED potential of substances requires expertise and a good understanding of the state-of-the-art tools and available methods. CEHTRA can provide you with the necessary guidance to obtain reliable results using the most appropriate methods and to provide a balanced and independent ED assessment by experts of your active substances, chemicals, or ingredients.

Key Services

Optimised assessment of ED properties

Generating new data

Data compilation for regulatory dossiers

Expert

statements

  • Existing regulatory data

  • Targeted bibliographic search

  • QSAR screening

  • Tailored testing strategies (based on in silico, in vitro and/or in vivo studies)

  • Study monitoring of ED specific studies

  • Robust study summaries

  • EFSA table and identification of lines of evidence

  • Reports on ED assessments of specific ingredients or formulations

  • Position papers on the relevance of ED potential of a substance for human health/environment

Value-added Services

In silico screening by QSAR experts

Bespoke services adapted to many domains

(biocides, PPP, cosmetics, chemicals…)

Experienced in-house (eco)toxicologists

Key Contact

Interested to know more? Our key contact for Endocrine Disruption services, Julien LEGHAIT will be happy to answer all your queries. You can email him or simply drop your query into the chat window below.

STUDIO TONELLI - PORTRAIT -WEB-12.jpg

Julien LEGHAIT

Coordinator of Endocrine Disruption services

julien.leghait@cehtra.com